Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX - Free Report) from a sell rating to a hold rating in a research note published on Saturday.

Several other equities research analysts have also recently weighed in on the stock. Benchmark dropped their price target on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Genelux in a research report on Monday, March 31st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $17.75.

Genelux Stock Down 6.5%

Shares of Genelux stock traded down $0.21 during trading on Friday, reaching $3.02. The company's stock had a trading volume of 141,738 shares, compared to its average volume of 191,512. Genelux has a 52-week low of $1.60 and a 52-week high of $5.89. The company has a market cap of $113.97 million, a price-to-earnings ratio of -3.43 and a beta of -0.49. The firm's 50-day moving average is $2.63 and its two-hundred day moving average is $3.08.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03. On average, equities research analysts anticipate that Genelux will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Genelux

Several institutional investors and hedge funds have recently modified their holdings of the stock. Woodward Diversified Capital LLC lifted its position in shares of Genelux by 15.2% in the 1st quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company's stock worth $3,945,000 after purchasing an additional 192,808 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of Genelux in the 1st quarter worth about $770,000. Heights Capital Management Inc. purchased a new stake in shares of Genelux in the 1st quarter worth about $644,000. Marshall Wace LLP lifted its position in shares of Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after purchasing an additional 52,958 shares during the period. Finally, LPL Financial LLC increased its stake in shares of Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after acquiring an additional 39,516 shares in the last quarter. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.